Pariglasgene brecaparvovec

布哌格基

Report date: 2023/10/26 17:10:41

Base Information

Drug NamePariglasgene brecaparvovec
Drug Alias NameAAV8G6PCDTX-401
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionGlucose-6-phosphatase stimulantsGene transference
TargetsGlucose-6-phosphatase
Therapy Area/IndicationsGlycogen Storage Disease Type I
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesDimension Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesUltragenyx Pharmaceutical Inc
Inactive CompaniesN/A
Active IndicationsGlycogen Storage Disease Type I
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A